{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T02:56:49Z","timestamp":1784170609473,"version":"3.55.0"},"reference-count":74,"publisher":"Informa UK Limited","issue":"1","license":[{"start":{"date-parts":[[2023,7,21]],"date-time":"2023-07-21T00:00:00Z","timestamp":1689897600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100017183","name":"Janssen Scientific Affairs","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017183","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Future Oncol."],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.2217\/fon-2023-0436","type":"journal-article","created":{"date-parts":[[2023,7,21]],"date-time":"2023-07-21T08:49:54Z","timestamp":1689929394000},"page":"39-53","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":13,"title":["Time to Next Treatment in Patients with Chronic Lymphocytic Leukemia Initiating First-Line Ibrutinib or Acalabrutinib"],"prefix":"10.1080","volume":"20","author":[{"given":"Ryan","family":"Jacobs","sequence":"first","affiliation":[{"name":"Atrium Health Levine Cancer Institute (Hematology), Charlotte, NC 28204, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoxiao","family":"Lu","sequence":"additional","affiliation":[{"name":"Janssen Scientific Affairs, LLC, Horsham, PA 19044, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0060-765X","authenticated-orcid":false,"given":"Bruno","family":"Emond","sequence":"additional","affiliation":[{"name":"Analysis Group, Inc., Montr\u00e9al, Qu\u00e9becH3B 0G7, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Morrison","sequence":"additional","affiliation":[{"name":"Analysis Group, Inc., Montr\u00e9al, Qu\u00e9becH3B 0G7, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederic","family":"Kinkead","sequence":"additional","affiliation":[{"name":"Analysis Group, Inc., Montr\u00e9al, Qu\u00e9becH3B 0G7, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Lefebvre","sequence":"additional","affiliation":[{"name":"Analysis Group, Inc., Montr\u00e9al, Qu\u00e9becH3B 0G7, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-H\u00e9l\u00e8ne","family":"Lafeuille","sequence":"additional","affiliation":[{"name":"Analysis Group, Inc., Montr\u00e9al, Qu\u00e9becH3B 0G7, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wasiulla","family":"Khan","sequence":"additional","affiliation":[{"name":"Janssen Scientific Affairs, LLC, Horsham, PA 19044, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda H","family":"Wu","sequence":"additional","affiliation":[{"name":"Janssen Scientific Affairs, LLC, Horsham, PA 19044, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zaina P","family":"Qureshi","sequence":"additional","affiliation":[{"name":"Janssen Scientific Affairs, LLC, Horsham, PA 19044, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moshe Yair","family":"Levy","sequence":"additional","affiliation":[{"name":"Baylor Scott & White Research Institute, Dallas, TX75204, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2023,7,21]]},"reference":[{"key":"e_1_3_9_3_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21590"},{"key":"e_1_3_9_4_1","unstructured":"National Cancer Institute Surveillance Epidemiology and End Results Program . Cancer Stat Facts: Leukemia \u2014 Chronic Lymphocytic Leukemia (CLL). (2022)."},{"key":"e_1_3_9_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25595"},{"key":"e_1_3_9_6_1","unstructured":"GAZYVA (obinutuzumab) . Prescribing Information. Genentech Inc South San Francisco CA (2022)."},{"key":"e_1_3_9_7_1","unstructured":"RITUXAN (rituximab) . Prescribing Information. Genentech Inc South San Francisco CA (2021)."},{"key":"e_1_3_9_8_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2019.236000"},{"key":"e_1_3_9_9_1","unstructured":"VENCLEXTA (venetoclax) . Prescribing Information. Genentech Inc South San Francisco CA (2022)."},{"key":"e_1_3_9_10_1","unstructured":"ZYDELIG\u00ae (idelalisib) . Prescribing Information. Gilead Sciences Inc Foster City CA (2014)."},{"key":"e_1_3_9_11_1","unstructured":"COPIKTRA (duvelisib) . Prescribing Information. Verastem Inc Needham MA (2018)."},{"key":"e_1_3_9_12_1","unstructured":"IMBRUVICA (ibrutinib) . Prescribing Information. Janssen Biotech Inc Horsham PA (2022)."},{"key":"e_1_3_9_13_1","unstructured":"CALQUENCE (acalabrutinib) . Prescribing Information. AstraZeneca Pharmaceuticals LP Wilmington DE (2022)."},{"key":"e_1_3_9_14_1","unstructured":"BRUKINSA (zanubrutinib) . Prescribing Information. BeiGene Ltd San Mateo CA (2023)."},{"key":"e_1_3_9_15_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-021-01054-w"},{"key":"e_1_3_9_16_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1509388"},{"key":"e_1_3_9_17_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1400376"},{"key":"e_1_3_9_18_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-018-0276-9"},{"key":"e_1_3_9_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30788-5"},{"key":"e_1_3_9_20_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1817073"},{"key":"e_1_3_9_21_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1812836"},{"key":"e_1_3_9_22_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021014960"},{"key":"e_1_3_9_23_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25638"},{"key":"e_1_3_9_24_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2021006434"},{"key":"e_1_3_9_25_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-2856"},{"key":"e_1_3_9_26_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2021.279012"},{"key":"e_1_3_9_27_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2020.1795159"},{"key":"e_1_3_9_28_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2021-153146"},{"key":"e_1_3_9_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30262-2"},{"key":"e_1_3_9_30_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-019-0602-x"},{"key":"e_1_3_9_31_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2211582"},{"key":"e_1_3_9_32_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.01210"},{"key":"e_1_3_9_33_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-09-806398"},{"key":"e_1_3_9_34_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24564"},{"key":"e_1_3_9_35_1","doi-asserted-by":"publisher","DOI":"10.1080\/17474086.2020.1800451"},{"key":"e_1_3_9_36_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.02698"},{"key":"e_1_3_9_37_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-022-00638-0"},{"key":"e_1_3_9_38_1","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000016328"},{"key":"e_1_3_9_39_1","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2017.23.2.236"},{"key":"e_1_3_9_40_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-021-01991-5"},{"key":"e_1_3_9_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2022.07.004"},{"key":"e_1_3_9_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2019.08.004"},{"key":"e_1_3_9_43_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12082311"},{"key":"e_1_3_9_44_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.2453"},{"key":"e_1_3_9_45_1","first-page":"716","article-title":"Validation of Real-World Data-based Endpoint Measures of Cancer Treatment Outcomes","volume":"2021","author":"Li Q","year":"2021","unstructured":"Li Q , Zhang H , Chen Z et al. Validation of Real-World Data-based Endpoint Measures of Cancer Treatment Outcomes. AMIA Annu Symp Proc 2021, 716\u2013725 (2021).","journal-title":"AMIA Annu Symp Proc"},{"key":"e_1_3_9_46_1","doi-asserted-by":"publisher","DOI":"10.14694\/EdBook_AM.2015.35.164"},{"key":"e_1_3_9_47_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40801-022-00332-4"},{"key":"e_1_3_9_48_1","doi-asserted-by":"publisher","DOI":"10.1080\/03007995.2020.1835851"},{"key":"e_1_3_9_49_1","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.2268"},{"key":"e_1_3_9_50_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26367"},{"key":"e_1_3_9_51_1","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyac260"},{"key":"e_1_3_9_52_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.720704"},{"key":"e_1_3_9_53_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-11-846808"},{"key":"e_1_3_9_54_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2021-148155"},{"key":"e_1_3_9_55_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00455-1"},{"key":"e_1_3_9_56_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1900574"},{"issue":"3","key":"e_1_3_9_57_1","first-page":"S26","article-title":"P-041 Real-world Comparison of Adherence Between Patients with Chronic Lymphocytic Leukemia Treated with Single-agent Ibrutinib or Acalabrutinib In First Line","volume":"97","author":"Lu X","year":"2022","unstructured":"Lu X , Emond B , Morrison L et al. P-041 Real-world Comparison of Adherence Between Patients with Chronic Lymphocytic Leukemia Treated with Single-agent Ibrutinib or Acalabrutinib In First Line. Am. J. Hematol. 97(S3), S26\u2013S26 (2022).","journal-title":"Am. J. Hematol."},{"key":"e_1_3_9_58_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2152-2650(22)01350-7"},{"key":"e_1_3_9_59_1","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2012.18.7.527"},{"key":"e_1_3_9_60_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-12-737346"},{"key":"e_1_3_9_61_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12875-019-1019-3"},{"key":"e_1_3_9_62_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2019.12.021"},{"key":"e_1_3_9_63_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-10-309807"},{"key":"e_1_3_9_64_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0056813"},{"key":"e_1_3_9_65_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022016953"},{"key":"e_1_3_9_66_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2022008325"},{"key":"e_1_3_9_67_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2152-2650(21)01760-2"},{"key":"e_1_3_9_68_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2021-148719"},{"key":"e_1_3_9_69_1","volume-title":"American Society for Clinical Oncology (ASCO) Annual Meeting.","author":"Sharman J","year":"2021","unstructured":"Sharman J , Egyed M , Jurczak W , Skarbnik A , Pagel J , Flinn I . Acalabrutinib + Obinutuzumab vs Obinutuzumab + Chlorambucil in Treatment-Naive Chronic Lymphocytic Leukemia: ELEVATE-TN 4-Year Follow-up. In: American Society for Clinical Oncology (ASCO) Annual Meeting. (2021)."},{"key":"e_1_3_9_70_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-168081"},{"key":"e_1_3_9_71_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.17994"},{"key":"e_1_3_9_72_1","volume-title":"64th Annual Americal Society of Hematology Annual Meeting and Exposition","author":"Brown JR","year":"2022","unstructured":"Brown JR . LBA-6 Zanubrutinib Demonstrates Superior Progression-Free Survival (PFS) Compared with Ibrutinib for Treatment of Relapsed\/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (R\/R CLL\/SLL): Results from Final Analysis of ALPINE Randomized Phase 3 Study. 64th Annual Americal Society of Hematology Annual Meeting and Exposition (2022)."},{"key":"e_1_3_9_73_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30909-9"},{"key":"e_1_3_9_74_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2019.03.014"},{"key":"e_1_3_9_75_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2019.10.009"},{"key":"e_1_3_9_76_1","doi-asserted-by":"publisher","DOI":"10.1093\/aje\/kwq433"}],"container-title":["Future Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.2217\/fon-2023-0436","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,23]],"date-time":"2024-06-23T06:44:52Z","timestamp":1719125092000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.2217\/fon-2023-0436"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,21]]},"references-count":74,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["10.2217\/fon-2023-0436"],"URL":"https:\/\/doi.org\/10.2217\/fon-2023-0436","relation":{},"ISSN":["1479-6694","1744-8301"],"issn-type":[{"value":"1479-6694","type":"print"},{"value":"1744-8301","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,21]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2023-05-16","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-06-30","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-07-21","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}